Signed By [CONTACT_232389]/Time (UTC)APPROVALSCONFIDENTIAL DOCUMENT/RECORD 
This document/record is electronically controlled; printed copi[INVESTIGATOR_42546]. 
System of Record: Regulatory Affairs Domain  
Document Name [CONTACT_232428]
11/17/2017 21:33:56
1.0
11/15/2017 14:18:49
CIP ReLINQuish Version 2 - 31Oct17
Document Approver
11/17/2017 20:08:06
11/02/2017 19:45:52
Document Approver
Document Author
11/07/2017 15:09:24
11/16/2017 15:09:59
11/02/2017 20:28:25
11/06/2017 18:16:28
Document Approver
Document Approver
CIP ReLINQuish Version 2 - 31Oct17.pdf

056-F154, Clinical Study Document Approval Form , Versio n 4.0 Page 2 of 3 
Version 1.0                                Medtronic Confidential  
15 November 2016        ReLINQuish CIP Sign Off Documentation  
  
Approver Name:  [CONTACT_241766] : Sr. Clinical Program Manager  
(Medical Advisor, Therapy SME ) 
e-signature  e-signature  
[CONTACT_241767] (DD/MMM/YYYY) 
 Approver Name:  [CONTACT_241766] : Regulatory Affairs Specialist  
(Regulatory (BU)  
Regulatory (GEO) ) 
e-signature  e-signature  
[CONTACT_241767] (DD/MMM/YYYY) 
 
Approver Name:  [CONTACT_241766] : Prin. Clinical Quality Compliance 
Specialist  
(Clinical Quality/Compliance)  
e-signature  e-signature  
[CONTACT_241767] (DD/MMM/YYYY) 
 
Approver Name:  [CONTACT_241766] : Statistics Manager  
(Biostatistician) 
e-signature  e-signature  
[CONTACT_241767] (DD/MMM/YYYY) 
 Approver Name:  [CONTACT_241766] : Clinical Monitoring Manager 
(Monitoring)  
e-signature  e-signature  
[CONTACT_241767] (DD/MMM/YYYY) 

056-F154, Clinical Study Document Approval Form , Versio n 4.0 Page 3 of 3 
Version 1.0                                Medtronic Confidential  
15 November 2016        ReLINQuish CIP Sign Off Documentation  
  
Approver Name:  [CONTACT_241766] : Sr. Clinical Safety Specialist  
(Safety) 
e-signature  e-signature  
[CONTACT_241767] (DD/MMM/YYYY) 
 

Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 1 of 67 
 
Medtronic Confidential 
This document is electronically controlled                                               056 -F25, v3.0 Clinical Investigation Plan Template  
  
 
Clinical Investigation Plan  
Clinical Investigation Plan/Study Title  ReLINQuish ( Relationship b etZeen /,N4 
subcutaneous impedance and right -Vided 
Kemodynamic measurements)  
Study Product Name  [CONTACT_241768]/Local Sponsor  Medtronic , Inc.  
[ADDRESS_293500] NE  
Mounds VieZ, MN [ZIP_CODE] 
Document Version 2.0
Lead Principal Investigator(s)   
Coordinating Investigator   
[INVESTIGATOR_241720].  
Any distribution,  copying,  or disclosure  Zithout  the prior Zritten  authori]ation of Medtronic is strictly 
prohibited.  Persons  to Zhom  the information  is disclosed  must NnoZ that it is confidential and that it 
may not be further disclosed by [CONTACT_476].  
  
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 2 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
 TaEle oI &ontentV  
&ontentV  
Table of ContentsÂ«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« 2  
1. GlossaryÂ«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« 5  
2. Synopsis Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«   
3. Introduction Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« 10 
3.1. BacNground Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« 10 
3.2. Purpose Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.  12 
4. ObMectives and Endpoints Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« 12 
4.1. ObMectives Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«. 12 
4.1.1.  Primary ObMective Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.Â«.. 12 
4.1.2.  Ancillary ObMective Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.  12 
4.2. Endpoints Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.  12 
4.2.1.  Primary Endpoint Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« 13 
5. Study Design Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.  13 
5.1. Duration Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« 14 
5.2. Rationale Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«..  [ADDRESS_293501] DescriptionÂ«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« 16 
6.1. General Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«..  16 
6.2. Manufacturer Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«..  1 
6.3. PacNaging Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.  1 
6.4. Intended Population Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« 1 
6.5. ETuipment Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« 1 
6.6. Product Use Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.  22 
6.. Product Training ReTuirements Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« 23 
6.. Product Receipt and TracNing Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« [ADDRESS_293502] Storage Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« [ADDRESS_293503] ReturnÂ«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.  [ADDRESS_293504] Accountability Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.  24 
. Se lection of SubMects Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.  24 
.1. Study PopulationÂ«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«..  24 
.2. SubMect Enrollment Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«..  25 
.3. Inclusion Criteria Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«..  25 
.4. E[clusion Criteria Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.  25 
. Study Procedures Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« 25 
.1. Schedule of Events Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.  25 
.1.1.  Data CollectionÂ«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« 25 
.2. SubMect Screening Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« 2 
.3. Prior and Concomitant Medications Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« 2 
.4. SubMect Consent Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« 2 
.5. Study Procedures Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.  2 
.5.1.  Baseline Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« 31 
.5.2.  Insertion Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.  31 
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 3 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
 .5.3.  Right +eart Catheteri]ation Procedure Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« 32 
.5.4.  Scheduled FolloZ -up Visits Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« 33 
.5.5.  Monthly CareLinN Transmissions Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« 34 
.5.6.  +ealthcare Utili]ation Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« 34 
.5..  Limited Posture Test Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.  35 
.5..  Posture TestÂ«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.. 35 
.6. Assessment of Safety Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.  35 
.. Recording Data Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.  35 
.. Deviation +andling Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«..  36 
.. Study E[it Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.  3 
. RisNs and Benefits Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«..  3 
.1. Potential RisNs Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«..  3 
.2. Potential Benefits Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.  41 
.3. RisN-Benefit Rationale Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« 41 
10. Adverse Event Assessments Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«..  42 
10.1. Definitions/Classifications Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«..  42 
10.1.1.  Device Deficiencies Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«..  42 
10.1.2.  Event Updates and ResolutionÂ«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«..  42 
10.2. Definitions/Classifications Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« 43 
10.3. Reporting of Adverse Events Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« 4 
10.3.1.  Adverse Events and Device Deficiency Classification Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«...  4 
10.3.2.  Adverse Events and Device Deficiency Reporting ReTuirements Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« [ADDRESS_293505] DeathÂ«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« 52 
10.4.1.  Death Data Collection Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.  52 
10.4.2.  Death Classification and Reporting Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«..  [ADDRESS_293506] Complaint Reporting Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« 53 
11. Data RevieZ Committees Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«..  54 
12. Statistical Design and Methods Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«..  54 
13. Ethics Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.  55 
13.1. Statement(s) of Compliance Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.  55 
14. Study Administration Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.  56 
14.1. Monitoring Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«..  56 
14.2. Data Management Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«..  [ADDRESS_293507] Access to Source Data/Documents Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.  5 
14.4. ConfidentialityÂ«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« 5 
14.5. CIP Amendments Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.  5 
14.6. Record Retention Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.  5 
14.. Publication and Use of Information Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«..  5 
14.. Suspension or Early Termination Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« 5 
14..1.  Planned study closure Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.  5 
14..2.  Early termination or suspension Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« 5 
14..3.  Study -Zide termination or suspensionÂ«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«..  5 
14..4.  Investigator/center termination or suspension Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.  5 
14..5.  Procedures for termination or suspension Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« 60 
15. References Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«..  61 
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 4 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
 16. Appendices Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.  62 
Appendi[ A: Patient Informed Consent Form Template Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.  63 
Appendi[ B: Draft data collection forms Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.  64 
Appendi[ C: ReLINQuish Study Procedure +andbooN Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â« 65 
Appendi[ D: Site InformationÂ«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«..  66 
1. Version +istoryÂ«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«Â«.  6 
 
  
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 8 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
 
The ReYeal /,14ÂŒ deYice and the  programmer are marNet released Eut once the 
inYestigational /,14ÂŒ +) RA0Zare is doZnloaded into the deYices they are considered 
inYestigational.  
Primary 
ObMective (s) The primary obMective is to characteri]e the relationship betZeen changes in Reveal LINQÂŒ subcutaneous impedance and cardiopulmonary hemodynamic 
measurements, resulting from:  1) short -term vasodilator and/or e[ercise 
challenges during right heart  catheteri]ation procedures or 2) long -term daily 
trends  of physiologic data, in patients Zith heart failure.
 
Ancillary 
ObMective To characteri]e the relationship betZeen changes in Reveal LINQÂŒ -derived data 
and other physiologic parameters Zith any acute decompensated heart failure (AD+F) events.  
 
Study Des ign The study is a prospective, non -randomi]ed, observational clinical study to be 
conducted at up to 5 centers  in the US.  Up to 30 subMects Zill be enrolled in the 
study. Study subMects Zill be folloZed for up to 1 months post -insertion or 3 
right heart  catheteri]ation procedures, Zhichever comes first. The e[pected study 
duration is appro[imately 3 years representing 1 months of enrollments and 1 months of folloZ -up. 
Sample Si]e  Up to 30 subMects  Zill be enrolled.   
Inclusion/  
E[clusion Criteria  Inclusion Criteria:  
x Patients meeting at least 1 of 3 criteria Zill be included in the study:  
R Patients Zith symptomatic systolic or diastolic heart failure Zho in the clinician Â¶s Mudgment have a high liNelihood of undergoing serial right 
heart catheteri]ations to aid in clinical management of their heart failure  
R Patients Zith dyspnea on e[ertion in Zhom e[ercise hemodynamics is indicated to diagnose  diastolic dysfunction  
R Patients Zho have  or Zill be implanted Zith a pulmonary artery 
pressure monitor  
x Patient is 1 years of age or older  
x Patient (or patientÂ¶s legally authori]ed representative) is Zilling and able to provide Zritten informed consent  
x Patient is Zilling and able to comply Zith the protocol, including folloZ -up 
visits and CarelinN transmissions.  
E[clusion Criteria:  
x Patient has an e[isting Medtronic  implantable cardiac device  
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 9 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.[ADDRESS_293508] device (LVAD)  
x Patient is pregnant (all females of child -bearing potential must have a 
negative pregnancy test Zithin 1 ZeeN of enrollment)  
x Patient is enrolled in another study that could confound the results of this 
study, Zithout documented pre -approval from a Medtronic study manager  
Study Procedures 
and Assessments  After enrollment, baseline data Zill be collected and a Reveal LINQTM device Zith 
LINQ-+F investigational RAMZare Zill be inserted.   
SubMects Zill be enrolled for 1 months and undergo scheduled folloZ -up visits at 
[ADDRESS_293509] 
had a right heart catheteri]ation (R+C) procedure Zithin the folloZ -up visit  
ZindoZ. If the subMect has an implantable pressure monitor, data Zill be collected 
from the monitor at the folloZ up visits.  
For subMects undergoing clinically indicated R+Cs as determined by [CONTACT_241736], a  tZo-month blanNing period post -insertion to alloZ for pocNet 
maturation Zould be preferred.  Prior to each R+C procedure, +olter mode Zill be 
enabled on the Reveal LINQTM device using a 200 programmer Zith 
investigational softZare, and a +olter monitor applied to the subMect to collect high-resolution impedance and ECG. After placement of the  PA catheter ( SZan -
Gan]), a standardi]ed procedure Zill be folloZed to ensure appropriate  placement 
of the pressure  reference  transducer . The R+C Zill be performed according to the 
participating institutionÂ¶s procedure.  ECG and hemodynamic data Zill be recorded 
on the lab recording system, a copy of Zhich Zill be provided to Medtronic.  Lab and +olter data Zill be synchroni]ed by [CONTACT_241737] ( e.g., briefly disconnecting or tappi[INVESTIGATOR_241721]). As part of the standard procedure, subMects  may be administered  a 
vasodilator or  e[ercise challenge. +olter mode Zill be disabled at the conclusion 
of the procedure.  These subMects  may e[it prior to 1 months after the 
completion of three R+C  procedures.   
Starting one month post -insertion, the subMect Zill utili]e the MyCareLinN +ome 
Monitor to manually transmit data on a monthly basis.  The subMects Zill be asNed 
to press the Patient Assistant Zhenever they feel increased shortness of breath 
compared to normal. +ealth Care Utili]ations (+CUs) (including hospi[INVESTIGATOR_36397]]ations, emergency department visits, outpatient treatment involving overnight stay, urgent care, or clinic visits) Zill be collected and reported on a +CU Case Report Form. Cardiovascular- related (including hypervolemia and hypovolemia) +CU 
information should be reported upon center aZareness and assessed at all visits.  
Safety Assessments  There are no defined safety endpoints in the ReLINQuish Study. Relevant Adverse Events (AEs), Device Deficiencies (DDs), and +ealth Care Utili]ations Zill be 
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 10 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
 collected throughout the study d uration and Zill be assessed and reported per 
regulatory reTuirements  
 Statistics  ReLINQuish is an observational characteri]ation study and therefore Zill not have 
poZered endpoints.  Analysis Zill include descriptive comparisons betZeen LINQTM 
impedance  and hemodynamic measurements.   
 ,ntroGuFtion   
 BacNground  
Filling pressures are considered to be an important diagnostic parameter in management of heart 
failure (+F) patients. +igher filling pressures are associated Zith higher risN for hospi[INVESTIGATOR_36397]]ations and 
mortality.1, 2 Monitoring and adMusting therapy based on pressures may improve patient symptoms 
and has been shoZn to reduce +F events.[ADDRESS_293510] generation implantable pressure sensor 
(Chronicle, Medtronic Inc. MN) consisted of a pressure sensor at the end of a lead that resided in the right ventricl e.
3 The measured pressures Zere used to estimate pulmonary artery diastolic 
pressure (ePAD). The pi[INVESTIGATOR_241722], COMPASS -+F, using this sensor failed to achieve 
the primary outcome of reducing +F- related events compared to the standard of care arm.[ADDRESS_293511] 
ever implantable sensor to measure filling pressures. The CardioMEMS pulmonary artery (PA) 
pressure sensor is an integral component of the FDA -approved CardioMEMS +F syste m (St. -ude 
Medical, MN). The sensor is implanted in a branch of the pulmonary artery and provides on-
command PA pressure  Zaveforms, pressure readings, and trend data over time (e.g. over a ZeeN). 
The clinician can remotely access these data and incorporate them in patient  management. For 
e[ample, a diuretic or another medication intervention may be made if the patientÂ¶s PA pressure  is 
out of the normal range. In fact such PA pressure -guided interventions Zere hallmarN of the 
successful C+AMPI[INVESTIGATOR_204732] .5 The trial shoZed that PA  pressure -guided +F management Zas 
associated Zith a 2 reduction in +F hospi[INVESTIGATOR_36397]]ation rate at 6 months, and 3 after an average folloZ -up of [ADDRESS_293512] s Zere managed using clinical 
assessment alone.  
Intrathoracic impedance is another +F management tool that has been available for over a decade 
in patients Zith implantable devices (ICD and CRT -D).
6  Impedance is measured across the RVcoil -
to-can vector, and a declining  trend in impedance and corresponding rise in derived OptiVol inde[ 
signifies higher risN of an +F event. Intrathoracic impedance is inversely correlated Zith pulmonary 
capi[INVESTIGATOR_241723] (PC:P).6  Both intrathoracic impedance and OptiVol inde[ have been 
shoZn to be associated Zith higher risN of +F hospi[INVESTIGATOR_36397]]ation and mortality.-   
The Reveal LINQÂŒ insertable cardiac monitor is a leadless device that is inserted in the region of the 
thora[. TZo electrodes on the body of the device continuously monitor the subMectÂ¶s subcutaneous ECG and, Zith investigational softZare, impedance.  Subcutaneous impedance derived from the 
Reveal LINQÂŒ insertable cardiac monitor may be of similar utility in patients Zithout implantable devices.   
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 11 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
 The Monitoring in Dialysis (MiD) study Zas conducted in renal failure patients implanted Zith a 
Reveal LINQÂŒ insertable  cardiac monitor. The results indicated subcutaneous impedance trends 
upZards Zith fluid removal  during dialysis sessions and doZnZards betZeen dialysis sessions. 
Therefore, the preliminary data shoZ that continuous  subcutaneous  impedance monitoring has a 
direct inverse  relationship to patient fluid status in both a detailed analysis and long -term trending 
analysis.10 
The LINQ +F study is utili]ing the Reveal LINQÂŒ device Zith an investigational LINQ +F RAMZare 
doZnload (version 1.1 or later) . The commercially available Reveal LINQÂŒ  device records and stores 
only subcutaneous ECG and activity from a single a[is accelerometer. The LINQ +F RAMZare 
enables the hardZare to record and  store impedance, temperature, activity, RR interval, R -Zave 
amplitude, posture change  count (based on ]- a[is accelerometer values) and [, y, and ]- a[is 
accelerometer  measurements periodically.  The doZnload also has a +olter mode in Zhich 
continuous impedance and ECG signals Zill be collected acutely and recorded on a DR220 +olter 
Recorder.  The purpose of the LINQ +F study is to characteri]e Reveal LINQÂŒ derived data from  
patients Zith heart failure by [CONTACT_241738] (AD+F) events. 
The study Zill also collect information regarding +F related  clinical events during the same period.    
Understanding the relationship betZeen  cardiopulmonary pressure and subcutaneous tissue 
impedance is of scientific interest, and could also be of potentially clinical utility. Understanding the correlation betZeen the tZo parameters (or lacN thereof) Zould help to determine treatment 
strategies Zhen certain impedance values/trends are noted in patients Zith  LINQ impedance data 
available (but no pressure data).   
The current proposal is to utili]e the LI NQ +F RAMZare doZnload to investigate the relationship 
betZeen LINQ impedance and direct hemodynamic measurements in patients Zith heart failure.  
Additionally, the relationship betZeen changes in LINQ impedance and other physiologic parameters 
during acute decompensated +F events Zill be characteri]ed.  Monthly doZnloads Zill be performed , 
and device data from the LINQ and PA pressure monitor ( Zhere applicable) Zill be collected at 
scheduled folloZ- up visits occurring  6, 12 and 1 months post -insertion of the LINQ device.  In 
subMects undergoing right heart catheteri]ation procedures, a +olter Recorder Zill be applied to 
collect continuous imp edance and ECG during  the procedure .  Similar to the LINQ +F clinical study, 
information regarding +F -related clinical events Zill be collected Zhile the patient is enrolled.  The 
study Zill be conducted in three patient populations:  
1. Patients Zith symptomatic systolic or diastolic heart failure Zho in the clinicianÂ¶s Mudgment have 
a high liNelihood of undergoing serial right heart catheteri]ations (R+C) to aid in clinical 
management of their heart failure  
2. Patients Zith dyspnea on e[ertion in Zhom e[ercise hemodynamics is indicated to diagnos e 
diastolic dysfunction  
3. Patients Zho have or Zill be implanted Zith a pulmonary artery pressure monitor 
 
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 12 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
  PurSose
The purpose of the ReLINQuish study is to characteri]e the relationship betZeen subcutaneous 
impedance  and direct hemodynamic measurements in patients Zith heart failure to assess cardiac 
function.  Additionally, the relationship betZeen changes in subcutaneous  impedance and other 
physiologic parameters during acute decompensated +F events Zill be characteri]ed.   
 2EMeFtiveV anG (nGpointV  
 OEMectiYes 
4.1.1.  Primary ObMective  
The primary obMective is to characteri]e the relationship betZeen changes in Reveal LINQÂŒ 
subcutaneous impedance and right heart hemodynamic measurements, resulting from:  1) short -
term drug  and/or e[ercise challenges during right heart  catheteri]ation procedures or 2) long -term 
daily trends  of physiologic data, in patients Zith heart failure.   
4.1.2.  Ancillary ObMective  
To characteri]e the relationship betZeen changes in Reveal LINQÂŒ -derived data and other 
physiologic parameters Zith any acute decompensated heart failure (AD+F) events.  
A heart failure event is defined as any cardiovascular- related (including hypervolemia)  
+ealth Care Utili]ations (+CUs) for any one of the folloZing events.  
x Admission Zith primary diagnosis of +F  
x Intravenous +F therapy (e.g. IV diuretics/vasodilators) or ultrafiltration at  
x any one of the folloZing settings:  
x Admission Zith secondary/tertiary diagnosis of +F  
x Emergency Department  
x Ambulance  
x Observation Unit  
x Urgent Care  
x +F/Cardiology Clinic 
 EndSoints  
It Zill be of interest to characteri]e the relationship betZeen changes in  Reveal  LINQÂŒ 
subcutaneous impedance and right heart hemodynamic measurements, resulting from:  1) short -
term drug and/or e[ercise challenges during right heart catheteri]ation procedures or 2) long -term 
daily trends  of physiologic data, in patients Zith heart failure.  
It Zill also be of interest to characteri]e the relationship betZeen changes in Reveal LINQÂŒ -derived 
data and other physiologic parameters Zith any acute decompensated heart failure (AD+F) events.   
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 13 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
 4.2.1. Primary Endpoint
As a feasibility study, ReLINQuish is not poZered to meet any endpoints.  
 StuG\ DeVign   
The ReLINQuish study is a prospective, non- randomi]ed, observational clinical study to be 
conducted at up to 5 centers.   Up to 30 subMects Zill be enrolled in the study. After enrollment, 
baseline data Zill be collected and a Reveal LINQTM device Zith LINQ- +F investigational RAMZare 
Zill be inserted.   
SubMects Zill be enrolled for 1 months and undergo scheduled folloZ- up visits at [ADDRESS_293513] had  a right heart catheteri]ation (R+C) 
procedure Zithin the folloZ -up visit  ZindoZ. 
For subMects undergoing clinically indicated R+Cs as determined by [CONTACT_241739], a  tZo-
month blanNing period post -insertion to alloZ for pocNet maturation Zould be preferred.  The 
subMect Zill remain enrolled for up to  1 months or 3 right heart  catheteri]ation (R+C) procedures, 
Zhichever comes first.  The intent is to capture  up to 3 R+Cs per patient as performed as standard 
of care at the investiga torÂ¶s institution. In this observational study,  physicians Zill be asNed to collect 
right heart pressure s during clinically indicated R+C procedures as determined by [CONTACT_30780].  The R+C Zill be performed according to the participating institutionÂ¶s procedure.  There 
are no study- related reTuirements around the performance or timing of the procedures, other than 
measures to collect comprehensive data and assure Tuality.   
Prior to each R+C procedure, +olter mode Zill be enabled on the LINQ device using a 200 programmer Zith investigational softZare, and a +olter monitor applied to the subMect to collect 
high-resolution impedance and ECG.  A standardi]ed procedure Zill be folloZed to ensure 
appropriate placement of the pressure transducer.  ECG and hemodynamic data Zill be recorded on 
the lab recording system, a copy of Zhich Zill be provided to Medtronic.  Lab and +olter data Zill be 
synchroni]ed by [CONTACT_241740] 
(e.g., briefly disconnecting or tappi[INVESTIGATOR_241724]). As part of the standard procedure, subMect s 
may be subMected to a drug or e[ercise challenge. +olter mode Zill be disabled at the conclusion of 
the procedure.  
Starting one month LINQ post-insertion, the subMect Zill utili]e the MyCareLinN +ome Monitor to 
manually transmit data on a monthly basis.  Site personnel Zill monitor for compliance Zith monthly 
transmissions and call the subMect as needed Z ith a reminder to transmit the data monthly.  The 
subMects Zill be asNed to press the Patient Assistant Zhenever they feel increased shortness of breath compared to normal. +ealth Care Utili]ations (+CUs) (including hospi[INVESTIGATOR_36397]]ations, emergency 
department visits, outpatient treatment involving overnight stay, urgent care, or clinic visits) Zill be 
collected and reported on a +CU Case Report Form. Cardiovascular- related (including hypervolemia 
and hypovolemia) +CU information should be reported upon center aZareness and assessed at all contacts Zith the subMects . 
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 14 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
 Selection of subMects, treatment of subMects, and evaluation of study data are potential sources of 
bias.  Methods incorporated in the study design to minimi]e potential bias include (but are not 
limited to):  
x Patients Zill be screen ed to confirm elibility for enrollment in Neepi[INVESTIGATOR_241725]/ 
e[clusion criteria  
x Regular monitoring visits Zill be conducted for adherence to the CIP and to verify source data 
x All study clini cians, participating site personnel, and Medtronic personnel Zill be trained on 
their respective aspects of the study using standar di]ed training materials  
 
In summary, potential sources of bias that may be encountered in this clinical study have been 
considered and minimi]ed by [CONTACT_54415].  
 Duration 
Study subMects Zill be folloZed for up to 1 months post -insertion or 3 right heart  catheteri]ation 
procedures, Zhichever comes first. The e[pected study duration is appro[imately 3 years representing 1 months of enrollments  and 1 months of folloZ -up.
 
 RationaOe  
Filling pressures are considered to be an important diagnostic parameter in management of heart 
failure (+F) patients. +igher filling pressures are associated Zith higher risN for hospi[INVESTIGATOR_36397]]ations and 
mortality.1, 2 Monitoring and adMusting therapy based on pressures may improve patient symptoms 
and has been shoZn to reduce +F events.5   
The Reveal LINQÂŒ insertable cardiac monitor is a minimally invasive, leadless device that is inserted 
in the region of the thora[.  Subcutaneous impedance  measured betZeen tZo electrodes on the 
body of the  device,  in addition to other sensor data  derived from the Reveal LINQÂŒ insertable 
cardiac monitor, may be of similar utility in patients Zithout implantable devices  and alloZ for +F 
management Zith less invasive measurements . 
The Monitoring in Dialysis (MiD) study Zas conducted in renal failure patients implanted Zith a Reveal LINQÂŒ insertable cardiac monitor. The results indicated impedance trends upZards Zith fluid removal during dialysis sessions and doZnZards betZeen dialysis sessions. Therefore, the preliminary data shoZ that continuous impedance monitoring has a direct inverse relationship to 
patient thoracic fluid status in both a detailed analysis and long term trending analysis.
10 
In the ReLINQuish study, the folloZ -up duration of 1 months, combined Zith selection of subMects 
Zith the liNelihood of undergoing serial R+Cs  or an implanted PA pressure  sensor , Zill alloZ for the 
assessment of correlation betZeen pulmonary artery pressures  (as surrogates of left side cardiac 
pressure s) and subcutaneous impedance over time.  Physiologic parameters captured during any 
AD+F events occurring Zhile the subMect is enrolled Zill further provide insight into correlations Zith 
LINQ impedance.  
Acute changes in subcutaneous impedance  
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 16 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
  
 
x +ypermia:  Increased cardiac output or rela[ation of the arterioles as a result of the interventions 
may lead to generali]ed increased tissue perfusion Zhich may be sensed subcut aneously.   
 3roGuFt DeVFription  
 *eneraO  
The study is utili]ing the Reveal LINQÂŒ device Zith an investigational LINQ +F RAMZare doZnload. The LINQ +F RAMZare enables high- resolution impedance and ECG to be streamed to a +olter 
monitor during a right  heart catheteri]ation procedure.  Surface ECG a nd hemodynamic data SZan-
Gan] catheter Zill be continuously  recorded on the lab system . Additionally, the RAMZare enables 
the hardZare to record and store impedance, temperature, activity, RR interval, R -Zave amplitude, 
posture change count (based on ]- a[is accelerometer values) and [, y, and ]- a[is accelerometer 
measurements periodically.  These data Zill be captured in monthly uploads via the MyCareLinN 
+ome Monitor.  The system components that Zill be used in this study are listed in the table beloZ.  
 
TaEle : Re/,N4uiVK StuG\ S\Vtem &omponentV 

Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 18 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.[ADDRESS_293514] or Zill be implanted Zith a pulmonary 
artery pressure monitor, Zill be included in the study.  
 ETuiSment  
Reveal LINQÂŒ Insertable Cardiac Monitor (ICM ) 
The Reveal LINQÂŒ is a leadless device that is recommended to be inserted in the region of the 
thora[. A specific recommended location  is provided Zithin the product manual. TZo electrodes on 
the body of the device continuously monitor the subMect Â¶s subcutaneous ECG. The device can store 
up to 30 min of ECG recordings from the patient -activated epi[INVESTIGATOR_1841] a nd up to 2 min of ECG 
recordings from the automatically detected arrhythmias . 
 
)igure : Reveal /,N4ÂŒ ,&M . 
Incision Tool
The Incision Tool is designed to create an incision of repeatable Zidth and depth Zith a single 
motion. It is composed of a blade, designed to maNe a repeatable incision, and handle, designed to ergonomically fit the clinicianÂ¶s hand. The Reveal LINQÂŒ Incision Tool is intended to maNe the 
incision simple and repeatable.  
 
)igure : Incision TooO 
 
Insertion Tool  
The Insertion Tool delivers the device through the incision and into the subcutaneous tissue. The 
tool is designed to ensure the device is delivered into a tight pocNet to ma[imi]e electrode contact 
[CONTACT_241741] a highly repeatable manner, and is composed of tZo parts: a handle 

Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 20 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
 )igure : MeGtroniF  3rogrammer
 
The Medtronic 200 Programmer Zith the LINQ +F investigational RAMZare Zill be used to 
doZnload the LINQ +F investigational RAMZare onto the Reveal LINQÂŒ device. LINQ +F 
investigational RAMZare is reTuired to activate additional sensors in the Reveal LINQÂŒ ICM. The LINQ +F investigational RAMZare Zill be loaded onto the 200 programmers designated for clinical use only. The 200 programmer Zith the LINQ +F investigational RAMZare Zill alloZ the ability to 
doZnload and remove the RAMZare into and from the device. In addition, the 200 programmer Zill 
be used during the scheduled folloZ -up visits. 
 
Medtronic LINQ +F Investigational RAMZare  
The LINQ +F investigational RAMZare (ver 1.1 or later) Zill provide the ability to enable the Reveal 
LINQÂŒ hardZare for the collection and storage of Reveal LINQÂŒ sensor data. The LINQ +F RAMZare enables the hardZare  to record and store impedance, temperature, activity, RR interval, 
R-Zave amplitude, posture change count (based on ] -a[is accelerometer values) and [, y, and ]-
a[is accelerometer measurements periodically. The device Zill collect and store this data every [ADDRESS_293515] amplitude and every 5 minutes for RR 
intervals, posture change count, and [, y, and ]- a[is accelerometer  values. In addition, impedance 
measurements are collected nightly and Zhen the Patient Assistant is used.  
Patient Assistant  
The Reveal Patient Assistant is a battery operated, hand -held telemetry device that enables the 
subMect, on e[periencing symptoms potentially indicative of a cardiac event, to manually trigger the 
Reveal LINQÂŒ ICM to c ollect and store an ECG record. The Reveal Patient Assistant is intended for 
unsupervised patient use aZay from a hospi[INVESTIGATOR_7708]. The Patient Assistant activates the data 
management feature in the Reveal LINQÂŒ ICM to initiate recording of cardiac event data in the 
implanted device memory.  
The subMects Zill be asNed to press the Patient Assistant Zhenever they feel increased shortness of 
breath compared to normal. In addition, the subMects Zill be asNed to press the Patient Assistant device to marN the beginning and end of their 6 Minute +all :alN test ONL< Zhen the DR220 +olter 
is not used. Additionally, the LINQ +F RAMZare enables the storage of a short segment of 
impedance  signal Zhen the Reveal Patient Assistant device is used.  
 
)igure : 3atient AVViVtant 
 

Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 21 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
 MyCareLinNÂŠ +ome Monitor 
The MyCareLinNÂŠ +ome Monitor is a device that enables the device diagnostic data (Zhich includes 
ECG data) to be transmitted directly from the implanted Reveal LINQÂŒ device to the Medtronic 
CareLinNÂŠ NetZorN for revieZ by [CONTACT_099]. The additional data that is stored in the device by 
[CONTACT_241742] +F RAMZare is also transmitted during a CareLinN transmission but Zill not be available for revieZ by [CONTACT_099].  
 
)igure : M\&are/inNÂŠ +ome Monitor 
 
DR220 +olter Monitor  
The NorthEast Monitoring, Inc. DR220 Digital Recorder is a +olter monitor that is commercially 
available and designed to facilitate the ambulatory cardiac monitoring of those subMects Zho may benefit from such monitoring on order of a physician, including but not limited to those Zith 
complaints of palpi[INVESTIGATOR_814], syncope, chest pains, shortness of breath, or those Zho need to be 
monitored to Mudge their current cardiac function, such as subMects Zho have recently received 
pacemaN ers. The DR220 Digital Recorder is intended for use Zith Medtronic System -B compatible 
implantable pulse generators, implantable cardiac defibrillators, and cardiac resynchroni]ation therapy devices and implantable cardiac monitors. A +olter monitor is an e[ternal bo[ used to record electrical heart signals from electrode patches attached to the sNin (ECG) as Zell as from the cardiac device (EGM). There are no contraindications for the use of a DR220 +olter monitor. The 
+olter monitor Zill be used in accordance Zith its labeling. Only trained study personnel should 
apply the monitors.  
 
The data obtained by [CONTACT_241743]]ed at the time of recording. After the recording is 
complete, the data must later be doZnloaded to a compatible NorthEast Monitoring, Inc. +olter 
analysis system to be analy]ed. No personal information Zill be entered and collected by [CONTACT_91511]220 
recorder.  
 
The DR220 +olter Recorder used in this study is a portable ECG device able to collect telemetry 
signals and marNer channel information from any Medtronic device for up to 4 hours. The +olter 
Recorder has application for any subMect Zith a Medtronic ICM. For the purposes of this study, the intended use of the +olter Recorder is to acutely uplinN continuous impedance and ECG signals that 
Zill be collected by [CONTACT_241742] +F RAMZare in the +olter mode. Since only the device data uplinN 

Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 22 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
 feature of the +olter Zill be used in this study, the device antenna Zill only be used and no ECG 
electrodes Zill be used.  
 
 
)igure : DR +olter 
 Product Use 
The Reveal  LINQTM device is a programmable cardiac monitor that continuously monitors a patientÂ¶s 
ECG and other physiological parameters.  
It Zill be implanted in all the subMects enrolled in the study and the device implant procedure Zill be 
performed as per routine practice according to the Clinician Manual. After implant, the investigational softZare Zill be doZnloaded onto the device maNing it interventional. In order to complete this installation, an ad -hoc [ADDRESS_293516] Zill be provided of:  
x A Patient Assistant that Zill alloZ him/her to record (marN) heart rhythm in case he/she e[periences any specific symptoms  that could be related to his/her cardiac condition, such as 
but not limited to fainting, palpi[INVESTIGATOR_814], di]]iness, and shortness of breath.  
x A CarelinN Monitor that Zill alloZ him/her to perform automatic daily transmissions and manual transmissions once a month.  
 
At every folloZ -up visit, a device interrogation Zill be performed in order to doZnload on a USB 
flash drive information recorded by [CONTACT_241744] (Cardiac Compass, +istograms, and Longest AF).  

Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 24 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.[ADDRESS_293517] be controlled by [CONTACT_13753]/or trained study center personnel. 
Investigational product Zill be stored in a secure location at the study center. The method of 
storage shall prevent the use of investigational devices/products for other applications than 
mentioned in this Clinical Investigation Plan. It is the responsibility of the investigator to correctly handle, store, and tracN the investigational products.  
  Product Return 
Investigator agrees to use the study devices solely for the purpose of the study. Medtronic Zill retain all rights of possession and oZnership in the study device and Investigator Zill acTuire no 
rights of possession and oZnership in the Study Devices pursuant to the Clinical Trial Agreement or 
otherZise. Upon the termination or e[pi[INVESTIGATOR_241726], Investigator Zill immediately return any unused disposable Study Devices and all non-disposable devices to Medtronic at MedtronicÂ¶s cost.  
Any disposable investigational product needs to be returned to Medtronic in case of device 
deficiency during the implant procedure  or during the folloZ -up visits. In that case they should be 
returned as soon as possible for investigation . 
Mailer Nits Zith prepaid US postage are available for use Zithin the [LOCATION_002] to send CRT, ICD, IPG, and leads to MedtronicÂ¶s CR+F Returned Product Analysis Lab. These mailers are si]ed to accommodate the devices and leads from a single patient or clinical event and are designed to meet US postal regulations for mailing bioha]ard materials.  To receive a Nit, please contact [CONTACT_241745] a study team member.  
  Product AccountaEiOity  
Documentation of investigational product allocation and tracNing is reTuired at each step of the process via the Product Accountability Log. It is the responsibility of the investigator to correctly 
handle, store, and tracN the investigational products. The investigational Product Accountability Log  
is provided to the center and Zill be used for tracNing of all investigational products. The log must 
be maintained at the center and updated Zhen the investigational product is received, used, disposed or returned to Medtronic.
 
 SeleFtion oI SuEMeFtV  
 Study PoSuOation 
Patients Zith dyspnea on e[ertion or symptomatic systolic or diastolic heart failure Zho have a high liNelihood of undergoing serial right heart  catheteri]ations (R+C) to aid in clinical diagnosis and/or 
management of their heart failure, or patients Zho have an implanted pulmonary artery pressure monitor, Zill be included in the study.
 
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 25 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
  SuEMect EnroOOment  
Patients must sign the patient informed consent form and meet all of the inclusion and none of the 
e[clusion criteria prior to being enrolled.  
 IncOusion Criteria  
x Patients meeting 1 of 3 criteria Zill be included in the study: 
1. Patients Zith symptomatic systolic or diastolic heart failure Zho have a high liNelihood of 
undergoing serial right heart catheteri]ations (R+C) to aid in clinical management of their heart failure  
2. Patients Zith dyspnea on e[ertion in Zhom e[ercise hemodynamics is indicated to diagnose 
diastolic dysfunction 
3. Patients Zho have or Zill be implanted Zith a pulmonary artery pressure monitor 
x Patient is 1 years of age or older  
x Patient (or patientÂ¶s legally authori]ed representative) is Zilling and able to provide Zritten 
informed consent  
x Patient is Zilling and able to comply Zith the protocol, including folloZ -up visits and Care LinN 
transmissions  
 E[cOusion Criteria
x Patient has an e[isting Medtronic implantable cardiac device.   
x Patient has a left ventricular assist  device (LVAD).  
x Patient is pregnant (all females of child -bearing potential must have a negative pregnancy test 
Zithin 1 ZeeN of enrollment)  
x Patient is enrolled in another study that could confound the results of this study, Zithout 
documented pre -approva l from a Medtronic study manager  
 
 StuG\ 3roFeGureV  
 ScKeduOe of EYents 
.1.1.  Data Collection  
TaEle : Data &olleFtion 
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 28 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
 the 3rincipal ,nYestigator or an authori]ed designee. A suEMect may only consent after information has 
Eeen giYen to the suEMect on all aspects of the clinical inYestigation that are releYant to the suEMectÂ¶s decision to participate.  
3rior to enrolling suEMects each site must haYe documented ,R% approYal of the ,nformed &onsent )orm ,& )orm and an Authori]ation to 8se and Disclose 3ersonal +ealth ,nformation/Research 
Authori]ation/other priYacy language as reTuired Ey laZ. Any changes to a preYiously approYed ,nformed &onsent )orm throughout the course of the study must Ee reYieZed and approYed Ey 0edtronic and the ,R% reYieZing the application Eefore Eeing used to oEtain consent or re consent a 
study suEMect. The documents must Ee controlled i.e. Yersioned and/or dated to ensure it is clear Zhich Yersions Zere approYed Ey the ,R%. 
The inYestigator must notify the suEMect of any significant neZ findings aEout the study that Eecome aYailaEle during the course of the study Zhich are pertinent to the safety and Zell Eeing of the suEMect 
as this could impact a suEMectÂ¶s Zillingness to participate in the study. ,f releYant approYal may Ee 
reTuested from suEMects to confirm their continuing informed consent in Zriting.  
The process of oEtaining informed consent shall:  
x Ensure that the Principal Investigator , or an authori]ed designee , obtains the informed consent.  
x Include all aspects of the clinical study that are relevant to the subMect
s decision to participate 
throughout the clinical study.  
x Avoid any coercion or undue improper influence on, or inducement of the subMect to participate.  
x Not Zaive or appear to Zaive the subMectÂ¶s legal rights.  
x Ensure the Informed Consent Form and an Authori]ation to Use and Disclose Personal +ealth Information/Research Authori]ation/other privacy language, as reTuired by [CONTACT_241746],  are given to the 
subMect in a non- technical language the subMect is able to read and understand.  
x 3roYide ample time and opportunity for the suEMect to read and understand the ,nformed 
&onsent )orm  to inTuire aEout details of the study and to consider participation. All Tuestions 
aEout the study should Ee ansZered to the satisfaction of the suEMect.  
x Include a personally dated signature [CONTACT_241769].   
x Include a personally dated signature [CONTACT_3265] [CONTACT_458] [INVESTIGATOR_241727]]ed designee 
responsible for obtaining the informed consent, as reTuired by [CONTACT_241747].  
x Provide the subMect Zith a copy of the Informed Consent Form and an Authori]ation to Use and Disclose Personal +ealth Information/Research Authori]ation/other privacy language as reTuired by [CONTACT_241746].  
x (nsure suEMects are notified of any significant neZ findings aEout the study that Eecome 
aYailaEle during the course of the study Zhich are pertinent to the safety and Zell Eeing of the 
suEMect as this could impact a suEMectÂ¶s Zillingness to participate in the study.  
 
,f informed consent  is oEtained the same day the suEMect Eegins participating in study related 
procedures it must Ee documented in the suEMectÂ¶s case history that consent Zas oEtained prior to 
participation in any study related procedures. ,t is Eest practice for the informed consent process to Ee 
documented in the suEMectÂ¶s case history regardless of circumstance.  
 ,n the eYent the suEMect cannot read and/or Zrite Zitnessed impartial third party informed consent 
Zill Ee alloZed proYided detailed documentation of the process is recorded in the suEMectÂ¶s case 
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 29 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
 history and the Zitness signs and dates the ,nformed &onsent  )orm . ,nformed consent shall Ee 
oEtained through a superYised oral process. An independent Zitness must Ee present throughout the 
process. The ,nformed &onsent  )orm and any other information must Ee read aloud and e[plained to 
the prospectiYe suEMect if alloZed Ey local laZ. The Zitness signs and personally dates the ,nformed 
&onsent )orm attesting that the information Zas accurately e[plained and that informed consent Zas 
freely giYen. The suEMect should Â³maNe his marNÂ´ sign or otherZise physically marN the document so 
as to indicate consent on the ,nformed &onsent )orm as Zell. The ,nformed &onsent )orm should document the method used for communication Zith the prospectiYe suEMect and the specific means Ey 
Zhich the prospectiYe suEMect communicated agreement to participate in the study. The original of the 
signed ,nformed &onsent )orm must Ee filed in the hospi[INVESTIGATOR_307]/clinical chart and/or Zith the suEMectÂ¶s 
study documents.  
 The ,nformed &onsent )orm and Authori]ation to 8se and Disclose 3ersonal +ealth 
,nformation/Research Authori]ation/other priYacy language as reTuired Ey laZ  must Ee aYailaEle for 
monitoring auditing and regulatory inspections. Any 0edtronic )ield personnel Zho support the 
Re/,14uish study must Ee aEle to reYieZ the suEMectÂ¶s signed and dated ,nformed &onsent )orm and 
Authori]ation to 8se and Disclose 3ersonal +ealth ,nformation/Research Authori]ation/other priYacy 
language as reTuired Ey laZ  and Yerify its completeness prior to proceeding Zith any study 
procedures. ,n the eYent the 0edtronic )ield personnel identify the ,nformed &onsent  )orm or 
Authori]ation to 8se and Disclose 3ersonal +ealth ,nformation/Research Authori]ation/other priYacy language as reTuired Ey laZ as Eeing incomplete the Re/,14uish  study procedures Zill not Ee 
alloZed to occur until the informed consent of the suEMect can Ee adeTuately and appropriately oEtained.  
:hen a patient and the Principal I nvestigator or authori]ed designee, as reTuired , have personally 
signed and dated the Informed Consent Form and Authori]ation to Use and Disclose Personal +ealth 
Information/Research Authori]ation/other privacy language, as reTuired by [CONTACT_241746], the patient is 
considered a subMect enrolled in the study. The date the subMect signed the Informed Consent Form 
and Authori]ation to Use and Disclose Personal +ealth Information/Research Authori]ation/other privacy language as reTuired by [CONTACT_241746] , must be documented in the subMectÂ¶s medical records.
  
 Study Procedures  
Data Zill be collected at the Baseline Visit, Insertion, 6 and 12- month folloZ -up visits, R+C 
procedure s, and monthly CareLinN transmissions. A tZo -month blanNing period post -insertion is 
recommended but not reTuired.  SubMects may be e[ited upon completion of 3 R+Cs.  
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 30 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
  

Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 31 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
  
)igure : SFKeGule oI (ventV  
.5.1.  Baseline  
The Baseline visit can be a standalone visit or can be performed on the same day of insertion prior 
to the insertion procedure.  
The folloZing information is reTuired to be collected in the CRF at the baseline visit prior to 
performing  the device implant:  
R Informed consent  
R Inclusion/e [clusion criteria  
R Medical history 
R Demographics 
R Physical e [amination , including pi[INVESTIGATOR_241728]  
R Medication assessment  
R Standard chemistry panel plus NT-proBNP  
R Symptoms and temperature (via ear is recommended)  
.5.2.  Insertion  
FolloZing the baseline visit, a  Reveal LINQÂŒ device  Zill be implanted in the subMect. The implant 
procedure Zill be performed in accordance Zith the hospi[INVESTIGATOR_307]Â¶s standard implant practice and in 
accordance Zith the Medtronic Reveal LINQÂŒ implant instructions.   
Use of the recommended implant locations is located in Figure 10 beloZ. Physicians should folloZ 
the Clinician Manual Zhen performing the Reveal LINQÂŒ implant.  
 
)igure : ReFommenGeG implant loFationV  

Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 32 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
 After the implant procedure, the investigational softZare Zill be doZnloaded onto the implanted 
LINQ device.  
The folloZing information Zill be collected: 
R Final system configuration, including LINQ, Patient Assistant and CarelinN Monitor serial numbers  
R Insertion procedure information, including location of inserted device  
R Device interrogation (save to media ) 
R Limited posture test  
.5.3.  Right +eart Catheteri]ation Procedure 
A tZo -month blanNing period post -insertion to alloZ for pocNet maturation Zould be preferred prior 
to the first right  heart catheteri]ation (R+C) procedure.   
Prior to each R+C procedure, +olter mode Zill be enabled on the LINQ device using a 200 
programmer Zith investigational softZare, and a DR220 +olter Recorder Zill be applied to the 
subMect to collect high- resolution impedance and ECG. See Appendi[ C for more information on 
applying the +olter.   
The R+C Zill be performed according to the participating institutionÂ¶s procedure . There are no 
study -related reTuirements around the performance or timing of the procedures, other than 
measures to collect comprehensive data and assure Tuality.  A standardi]ed procedure Zill be folloZed to ensure appropriate placement of the pressure transducer. The location of the pressure 
transducer Zill be measured from the substernal notch doZn and recorded at the first procedure.  
This measurement Zill be used to ensure consistent placement of the pressure transducer at 
subseTuent procedures. Both the pro[imal and distal ports of the SZan- Gan] catheter Zill be 
connected for continuous recording of right atrial and pulmonary artery pressures. Cardiac output 
and systemic blood pressure Zill be measured freTuently throughout the procedure  and at least 
every 2 minutes during the drug or e[ercise challenge and recovery . ECG and hemodynamic 
Zaveform data Zill be recorded on the lab recording system, a copy of Zhich Zill be provided to 
Medtronic.  Lab and +olter data Zill be synchroni]ed by [CONTACT_241740] ( e.g., briefly disconnecting or tappi[INVESTIGATOR_241724]).  
As part of the standard procedure, subMects may be administered  a n acute  drug or e[ercise 
challenge. Alternatively, subMects Zith an implanted PA pressure  monitor may undergo a right heart 
catheteri]ation procedure Zithout any associated drug or e[ercise challenge. The +olter Zill continue to record data throughout the recovery/observation period  Zith the subMect r emaining 
supi[INVESTIGATOR_241729].  The timing and description of any positional changes Zill be noted in the CRFs. At the conclusion of the recovery period, the posture test Zill be 
performed, the +olter recorder Zill be removed, and +olter mode Zill be disabled  (see Appendi[ C 
for more information).  
The folloZing information Zill be collected 
prior to  each right heart catheteri]ation procedure: 
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 33 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
 x Physical e[amination, including pi[INVESTIGATOR_241728]  
x Medication  assessment  
x Standard chemistry panel plus  NT-proBNP (only if the  procedure visit is substituting for the 
6- or 12- month scheduled folloZ -up visit) 
x Symptoms and temperature (via ear is recommended)  
x N<+A functional classification assessment  
 
The folloZing additional information Zill be collected at each right heart catheteri]ation procedure: 
x Device data  
x Posture t est 
x +emodynamic measurements  
x +olter (DR220) data  
.5.4.  Scheduled FolloZ-u p Visits  
After receiving notice of successful LINQ insertion, Medtronic Zill provide the target dates and 
ZindoZs for each visit to the implanting center. Should a subMect miss a visit or the visit fall outside 
the pre -specified ZindoZ, a study deviation must be reported and the original folloZ -up schedule 
maintained for subseTuent visits. Data analyses include folloZ -up visits, regardless of Zhether the 
visit occurs Zithin the ZindoZ. Therefore, a late visit is preferred over a missed visit but must be accompanied b y a deviation. FolloZ -up visit ZindoZs are listed in Table [ADDRESS_293518]-insertion.  
TaEle  3oVt ,nVertion )olloZ 8p 9iVit :inGoZV  
SFKeGuleG 
IolloZ up viVit  :inGoZ  
(&alFulateG Ga\V poVtinVertion ) 
:indoZ Start  Target :indoZ End  
6 month  163 13 203 
12 month  335 365 35 
E[it
  51 54 5 

SubMects Zill e[it at appro[imately 1 months, or after completing 3 right heart catheteri]ation procedures, 
Zhichever comes first.  It Zill not be considered a study deviation if the date of e[it of a subMect completing 3 R+Cs occurs outside of the E[it visit ZindoZ.  
The subMect can forego a scheduled folloZ -up visit if he/she had a right heart catheteri]ation 
procedure in the same ZindoZ.  
The folloZing information is to be collected at the 6 -month  and 12-month folloZ -up visits:  
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 34 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
 x Physical e[amination, including pi[INVESTIGATOR_241728]  
x Medication assessment  
x Standard chemistry panel plus NT -proBNP  
x Symptoms and temperature (via ear is recommended)  
x LINQ device data  
x Implanted PA pressure monitor data (if applicable)  
x N<+A functional classification assessment  
x Posture t est  
x 6M+: (optional)  
 
The folloZing information is to be collected at E[it:  
x Reason for e[it  
x +CU and AEs  
x Medication assessment  
x LINQ device data  
x Implanted PA pressure monitor data (if applicable)  
x LINQ +F RAMZare removal from LINQ device  
.5.5.  Monthly CareLinN Transmissions 
Starting one month post -insertion, the subMect Zill utili]e the MyCareLinN +ome Monitor to manually 
transmit data on a monthly basis.  Site personnel Zill monitor that the monthly transmissions are 
occurring and call the subMect as needed Zith a reminder to transmit the data monthly. +ealth Care  
Utili]ations (+CUs) (including hospi[INVESTIGATOR_36397]]ations, emergency department visits, outpatient treatment 
involving overnight stay, urgent care, or clinic visits) Zill be collected and reported on a +CU Case Report Form. Cardiovascular- related (including hypervolemia and hypovolemia) +CU information 
should be reported upon center aZareness and assessed at all visits.  
 
.5.6.  +ealthcare Utili]ation 
Cardiovascular- related +ealth Care Utili]ations (+CUs) (including hypervolemia and hypovolemia) 
Zill be collected.  This includes the folloZing: 
x Unscheduled clinic visit (including subMect- initiated phone calls if the subMect is e[periencing CV -
related symptoms)  
x Scheduled clinic visit (if the subMect is e[perienceing CV- related symptoms)  
x +ospi[INVESTIGATOR_241730]  
x Urgent care visit  
x Other outpatient utili]ation Zith overnight stay  
x Emergency department visit  
x Inpatient hospi[INVESTIGATOR_36397]]ation  
 
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 35 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
 +CU information should be reported upon center aZareness and assessed at all visits including the 
monthly telephone visits.  If multiple +CUs occur Zithin the same day, data from all +CUs can be 
captured on one eCRF.  
.5..  Limited Posture Test  
A limited posture test Zill be conducted at the Reveal LINQÂŒ insertion. SubMects Zill be reTuested to 
be put in tZo different postures: standing and supi[INVESTIGATOR_241731]. During each posture, the Medtronic 200 Programmer Zith the LINQ +F investigational RAMZare Zill be used to store the [, y, and ]-
a[is accelerometer values to calibrate the posture measurements. Refer to Appendi[ C for more 
details.  
.5..  Posture Test  
A posture test Zill be conducted at each right heart catheteri]ation procedure, and at 6 Month and 12 Month scheduled visits in subMects Zith implanted PAP sensors. SubMects Zill be reTuested to be 
put in four different postures: standing, supi[INVESTIGATOR_241731], lying  doZn on left side and lying doZn on 
right side. During each posture, the Medtronic 200 Programmer Zith the LINQ +F investigational 
RAMZare Zill be used to store the [, y, and ]- a[is accelerometer values to calibrate the posture 
measurements. Refer to Appendi[ C for more details.  
 Assessment of Safety 
There are no defined safety endpoints in the ReLINQuish Study.  Relevant Adverse Events (AEs), Device Deficiencies (DDs), and +ealth Care Utili]ations Zill be collected throughout the study 
duration and Zill E e reYieZed Ey the 0edtronic Safety RepresentatiYe for reporting per regulatory 
reTuirements
.  Further information on the collection of AEs and DDS is discussed in Section 11 . 
 Recording Data 
Source data is all information original records of clinical findings oEserYations or other actiYities in 
a clinical trial necessary for the reconstruction and eYaluation of  the trial. Source data are contained 
in source documents. ([amples of these original documents and data records include: hospi[INVESTIGATOR_2553] clinical and office charts laEoratory notes memoranda suEMectsÂ¶ diaries or eYaluation 
checNlists pharmacy dispensing records recorded data from automated instruments such as 
hospi[INVESTIGATOR_241732] +olter 3D) reports SD cards copi[INVESTIGATOR_241733] microfiches photographic negatiYes microfilm or magnetic media [ rays suEMect files and records Nept at the pharmacy at 
the laEoratories and at medico technical departments inYolYed in the clinical trial.  
The inYestigator Zill clearly marN clinical records to indicate that the suEMect is enrolled in this clinical 
study.  
Study ZorNsheets may Ee used and are considered as source documentation.  
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 36 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
 The data reported on the e&R)s shall Ee deriYed from source documents and Ee consistent Zith 
these source documents and any discrepancies shall Ee e[plained in Zriting. ,f applicaEle the 
e&R) may Ee considered source for the folloZing data collection elements Eut not limited to:  
 
x (nrollment 1otification  
R Site assigned patient reference  
x %aseline  
R AdministratiYe ,nformation  
R &ardiac Disease &lassification  
x DeYiations  
The site is responsiEle to record all trial related source data enaEling the sponsor to reconstruct the 
complete course of the clinical trial. Source data Zill Ee transcriEed to and reported through the &R) accordingly. A source data identification list Zill Ee proYided to the sponsor for approYal prior to 
commencing the clinical part of the trial. The list Zill Ee filed in the inYestigator site file.  
:here copi[INVESTIGATOR_241734] these shall Ee signed and dated Ey a memEer of the inYestigation site team 
Zith a statement that it is a true reproduction of the original source document.  
 DeYiation +andOing  
A study deviation is defined as an event Zithin a study that did not occur according to the Clinical 
Investigation Plan or the Clinical Trial Agreement.  
Prior approval by [CONTACT_241748] e[pected in situations Zhere the investigator anticipates, contemplates, or maNes a conscious decision to  deviate. Prior approval is not reTuired Zhen a 
deviation is necessary to protect the safety, rights or Zell- being of a subMect in an emergency or in 
unforeseen situations beyond the investigatorÂ¶s control (e.g. subMect failure to attend scheduled folloZ -up visits, inadvertent loss of data due to computer malfunction, inability to perform reTuired 
procedures due to subMect illness).  
For medically Mustifiable conditions Zhich preempt a subMectÂ¶s ability to complete a study- reTuired 
procedure, it may be permitted to report only one deviation Zhich Zill apply to all visits going forZard. This may also apply for other unforeseen situations (e.g. the subMect permanently refuses to complete a study reTuired procedure and the data Zill not contribute to a study end  point 
analysis). +oZever, prior approval from Medtronic is reTuired for such situations.  
All study deviations must be reported on the Case Report Form regardless of Zhether medically Mustifiable, pre -approved by [CONTACT_13735], an inadvertent occurrence, or taNen to protect the subMect in 
an emergency. The deviation must be recorded Zith an e[planation.  Multiple deviations of the same type at the same visit may be reported on one case report form if they occur at the same date/visit and they have the same roo t cause.  
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 37 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.[ADDRESS_293519]Â¶s consent, or is made to protect the 
life or physical Zell -being of a subMect in an emergency, the deviation must be reported to the 
Institutional RevieZ Board (IRB) as Zell as Medtronic Zithin five (5) ZorNing days. Reporting of all other study deviations should comply Zith IRB policies and/or local laZs and must be reported to Medtronic as soon as possible upon the center becoming aZare of the deviation. Reporting of deviations must comply Zith IRB policies, local laZs, and/or regulatory agency reTuirements.  
Medtronic is responsible for analy]ing deviations, assessing their significance, and identifying any 
additional corrective and/or preventive actions (e.g. amend the Clinical Investigation Plan, conduct 
additional training, and terminate the investigation). Repetitive or serious investigator compliance issues may result in initiation of a corrective action plan Zith the investigator and site, and in some cases, necessitate suspending enrollment until the problem is resolved or ultimately terminating the investigator
s participation in the study. Medtronic Zill provide center- specific reports to investigators 
summari]ing information on deviations that occurred at the investigational site on a periodic basis.
 
 Study E[it  
At study e[it, a CRF is reTuired for all subMects e[cept in the case of death.  Prior to e[iting a subMect from the study, it is recommended to folloZ the subMect until all ongoing system and/or procedure related AEs  are resolved or unresolved Zith no further actions planned.  FolloZing e[it, subMects Zill 
continue to receive standard medical care Zith their primary/enrolling physician.  Upon e[iting from the study, no further study data Zill be collected and no further study visits Zill occur for the subMect.  All data available through the time of the subMectÂ¶s e[it Zill be used for analysis.  
SubMects Zill remain in the study until 1 months, or upon completing 3 right heart catheteri]ation 
procedures, Zhichever comes first.   
 The subMect  may also be e[ited from the study for any of the folloZing situations:  
x SubMect has  completed folloZ -up 
x SubMect lost to folloZ -up 
x SubMect death  
x SubMect has an e[plant Zithout the intent to re -implant  
x SubMect did not meet inclusion/e[clusion criteria  
x SubMect did not provide consent or data use protection authori]ation 
x SubMect chooses to ZithdraZ (e.g., consent ZithdraZal, relocation to another geographic location)  
x Investigator deems ZithdraZal necessary (e.g., medically Mustified, inclusion/e[clusion criteria not met, failure of subMect to maintain adeTuate study compliance)  
x Lead or generator replacement  
 
If subMect is not lost to folloZ up, the folloZing information /procedure  is reTuired to be 
collected /performed  at e[it  (Zhere available) : 
x Reason for e[it +CU and AEs  
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 38 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
 x LINQ device data  
x Implanted PA pressure monitor data (if applicable)  
x Medication assessment  
x LINQÂŒ +F RAMZare removal from LINQÂŒ device  
 
In the case that the subMect is determined to be lost  to folloZ -up, details of a minimum of tZo 
attempts and the method of attempt (e.g., one letter and one phone record or tZo letters) to 
contact [CONTACT_241749]. In addition, folloZ the regulations set forth by [CONTACT_241750].  
 RiVNV anG %eneIitV  
 PotentiaO RisNs  
 
The potential risNs associated Zith the ReLINQuish study Zere identified and have been successfully 
mitigated. Any potential risNs associated Zith this study are further minimi]ed by [CONTACT_241751].  
In addition, investigators Zill be actively involved in the implantation and regular folloZ -up of the 
subMects implanted Zith the Reveal LINQÂŒ Zith investigational RAMZare systems. At each office folloZ -up visit reTuired per protocol, the LINQÂŒ device Zill be interroga ted, device data collected to 
verify appropriate device function and patientÂ¶s health assessed for any adverse events.  
 Medtronic has further minimi]ed the possibility of risNs by [CONTACT_241752] -clinical testing prior to the 
ReLINQuish clinical study, implementing Tuality control measures into softZare development 
processes, providing guidelines for subMect selection and evaluation, and providing adeTuate training instructions and labeling.  
There are potential risNs and side effects associated Zith a Reveal LINQÂŒ device implant and e[plant procedures:  
x Allergenic reaction or device reMection phenomena including local tissue reaction  
x E[cessive device migration (internal pocNet device movement as Zell as device e[ternali]ation) 
x PocNet infection  
x Erosion through the sNin  
x Tissue / vascular trauma  
 
Possible additional risNs for participating in this study include the folloZing (although others are 
possible):  
 
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 40 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
 E[cessive  ICM migration 
folloZing implant procedure 
(internal device movement and 
e[ternali]ation) x :ound checN folloZing implant, per siteÂ¶s practi ce 
x Training and information for user on the Reveal LINQTM 
implant techniTue and incision closure techniTues  
x Use of the implant tools to create a small incision and tight pocNet.  
x Reveal LINQ
TM ICM design includes anti- migration 
features on the header  
x Investigator discretion to remove if deemed medically 
necessary  
Blunt tissue inMury/trauma or vascular trauma from implant/e[plant procedure  x Insertion tool has a stop position the prevents insertion of the probe beyond the distance reTuired for implant  
x Training on the correct use of implant tools  
x Selection of e[perienced investigator  
Pain or scarring from implant/e[plant procedure  x Use of incision tool Zill produce the smallest incision possible for implant  
x Small devices si]e minimi]es the invasiveness of the 
implant and e[plant procedures  
Undesired device interactions 
Zith the investigational 
RAMZare  x Device interactions analysis to ensure there are no undesired interactions betZeen the LINQ +F 
investigational RAMZare and the Reveal LINQ
TM 
firmZare  
x LINQ +F investigational RAMZare is designed to be 
automatically removed by [CONTACT_241753]/une[pected ICM e[plant  x The proMected longevity of Reveal LINQ
TM device Zith 
investigational LINQ +F RAMZare shoZs a 5 month decrease in average  proMected service life compared to 
a device Zithout the RAMZare. The e[act service life of 
each device Zill vary depending on each subMectÂ¶s use.  
Electromagnetic interference  x Design consideration and precautions in place for the Revela LINQ
TM system remain effective to address EMI 
risNs 
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 41 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
 Pain or stimulation effects from 
impedance measurements over 
duration of implant  x The amount of current inMected as part of the 
impedance measurements has been minimi]ed to prevent subMect harm  
x Design controls in place to protect against fault 
conditions  
Missing/Misleading information causing inappropriate medical intervention  x Data integrity checNs have been implemented  
x Validation testing of the system set -up Zill be 
performed  
,mproper /,14ÂŒ +) 
inYestigational RA0Zare 
access and actiYation  x Access code and preconditions are in place for 
appropriate activation  
x Data integrity checNs have been implemented  
Undesirable interaction of LINQ +F impedance measurement Zith concomitant implanted 
cardiac device (IPG/ICD/ CRT -
P/D) t herapy delivery  x Pre-clinical testing prior to the ReLINQuish clinical study 
Undesirable interaction of Tel- B 
Zith concomitant implanted 
devices  x Pre-clinical testing prior to the ReLINQuish clinical study 
x E[lcusion of Medtronic IPGs, ICDs, and CRTs  
 
 PotentiaO Benefits 
The ReLINQuish study may offer no benefit to the subMect. SubMects may benefit from continuous 
arrhythmia monitoring Zith the Reveal ICM, as this monitoring could result in diagnosis of Atrial Fibrillation (or other arrhythmias) and comprehensive evaluation of symptoms on an earlier and more conclusive basis than Zhat Zould be possible Zithout an implantable cardiac monitor.  
The information gained from this study could result in the improved management of other patients 
receiving a Reveal  LINQÂŒ device in the future. Additionally,  information collected from this study 
may assist in the design of neZ product(s)/therapy(ies) and/or instructions for use.   
 RisN Benefit RationaOe 
Since the differences betZeen the Reveal LINQTM marNet -released de vice and the Reveal LINQTM 
device Zith the LINQ investigational RAMZare doZnload are minimal, both devices are used in accordance Zith the Reveal LINQ
TM implant manual and/or user manual, as applicable . The risNs 
associated Zith the device are similar as Zould be the case if the subMect received a Reveal LINQTM 
device outside  the study conte[t. The risNs introduced by [CONTACT_241742] +F investigational RAMZare are 
being evaluated and risN control measures being implements to reduce the risN to as loZ as possible to minimi]e subMect harm.  
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 42 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.[ADDRESS_293520] Zas not enrolled in the study. +ence, for individual subMects, participation 
in the study may have greater benefit than risN. Moreover, the value of the NnoZledge to be gained 
by [CONTACT_241754]. Lastly, the prospective benefit to subMects of having  Reveal LINQ
TM cardiac monitoring, Zith the potential to diagnose life-
threatening arrhythmias, may provide the subMec t Zith clinical benefit.  
 AGverVe (vent AVVeVVmentV  
  Definitions/COassifications
Reveal LINQÂŒ system and procedure -related adverse events Zill be collected  throughout the study 
duration, starting at the time of signing the Patient Informed  Consent Form.  In addition, all serious 
adverse events (SAEs) leading to death should be reported, regardless of relatedness.  
Reporting of these events to Medtronic Zill occur on an AE Form, including date of AE, treatment, 
resolution, assessment of both the seriousness of the AE and the relatedness to the device or procedure.  
(ach A( must Ee recorded on a separate A( e&R).  Documented pre -e[isting conditions are not 
considered AEs unless the nature or severity of the condition has Zorsened.  Unavoidable AEs, listed in 
Table 6, need not be reported unless the AE Zorsens or is present outside the stated timeframe post -
insertion.  
For AEs that reTuire immediate reporting ( see Table 6), initial reporting may Ee done Ey contact[CONTACT_241755].  The original completed AE CRF must be submitted to Medtronic as soon as possible.   
Any medication, Zhether cardiovascular or not, associated Zith the treatment of an AE must be reported.  
Medication changes that are not related to adverse events Zill not be collected.  
SubMect deaths are also reTuired to be reported.  Refer to Section 11.[ADDRESS_293521] Death collection and 
reporting reTuirements.
 
10.1.1.  Device Deficiencies  
Device deficiency (DD) information Zill be collected throughout the study and reported to Medtronic. 
Note that DDs that result in an Adverse Device Effect (ADE) to the subMect should be captured ason 
an AE CRF only. 
10.1.2.  Event Updates and Resolution  
For any changes in status of a previously reported AE  (i.e. change in actions taNen, change in 
outcome, change in relatedness), information needs to be updated on, or added to the original AE 
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 43 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.[ADDRESS_293522] dies or e[its the study , 
or until study closure, Zhichever occurs first.  
At the time of study e[it, all collected  AEs Zith an outcome of Â´UnresolvedÂ´  must be revieZed and 
an update to the original AE must be reported.  At a minimum, if there are no changes to the 
description, relatedness, test and procedures or actions taNen, the outcome must be updated to 
reflect Â³Unresolved at time of study e[itÂ´. 
  DeIinitionV/&laVViIiFationV  
:here the definition indicates Â³deviceÂ´, it refers to any device used in the study.  This might be the 
device under investigation, or any marNet released com ponent of the system , and includes but is not 
restricted to: the Reveal LINQTM, the programmer, and insertion tools.   
TaEle : AGverVe (vent anG DeviFe DeIiFienF\ DeIinitionV 
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 45 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
 Reveal LINQ System Related
(includes all implantable 
components and features, associated introduction tools, operational and installed softZare and programmers as defined in the Clinical Investigation Plan)  An adverse event that results from the presence or 
performance of any component of the system.  Device -related: An adverse event that results from the 
presence or performance (intended or otherZise) of the device.  
RAMZare-related
: An adverse event that results from the 
presence or performance (intended or otherZise) of the 
RAMZare. 
 
Programmer Related:  An adverse event that results from 
the presence or performance (intended or otherZise) of the programmer 
 
Insertion T ool Related: An adverse event that results from 
the presence or performance (intended or otherZise) of the iinsertion tool.  
 
+olter Related: An adverse event that results from the 
presence or performance (intended or otherZise) of the 
implant tool.  
Cardiovascular Related  An Adverse Event relating to the heart and the blood vessels 
or the circulation (e.g. Atrial Fibrillation, Myocardial Infarction, stroNe, perivascular disease) 
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 46 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
 Not Related Relationship to the deYice or procedures can Ee e[cluded 
Zhen:  
Âƒ The event is not a NnoZn side effect of the product 
category the device belongs to or of similar devices 
and procedures  
Âƒ The event has no temporal relationship Zith the 
use of the device or the procedures  
Âƒ The serious event does not folloZ a NnoZn response pattern to the medical device (if the response pattern is previously NnoZn) and is biologically implausible 
Âƒ The discontinua
tion of medical device application or 
the reduction of the level of activation/e[posure Â± Zhen clinically feasible Â± and reintroduction of its 
use (or increase of the level of activation/e[posure) 
do not impact the serious event  
Âƒ The event involves a body- site or an organ not 
e[pected to be affected by [CONTACT_10398]  
Âƒ The serious event can be attributed to another 
cause (e.g., an underlying or concurrent illness/clinical condition, an effect of another device, drug, treatment, or other risN factors) 
Âƒ The event does not depend on a false result given 
by [CONTACT_132621] (Zhen applicable)
 
Âƒ +arms to the subMect are not clearly due to use 
error  
Âƒ In order to establish the non- relatedness, not all 
the criteria listed above might be met at the  same 
time, depending on the type of device/procedures 
and the event.  
8nliNely  The relationship Zith the use of the deYice seems not 
releYant and/or the eYent can Ee reasonaEly e[plained Ey 
another cause Eut additional  information may Ee oEtained.  
Possible  The relationship Zith the use of the inYestigational deYice is 
ZeaN Eut  cannot Ee ruled out completely. AlternatiYe causes 
are also possiEle e.g. an underlying or concurrent illness/ 
clinical condition or/and an effect of another  deYice drug or 
treatment. &ases Zere relatedness cannot Ee assessed or no information has Eeen oEtained should also Ee classified 
as possiEle.
Probable  The relationship Zith the use of the inYestigational deYice 
seems releYant and/or the eYent cannot reasonaEly 
e[plained Ey another cause Eut additional information may 
Ee oEtained.  
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 52 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
   SuEMeFt DeatK  
10.4.1.  Death Data Collection  
All subMect deaths must be reported by [CONTACT_241756] (AE Zith outcome of  
fatal) as soon as possible after the investigator first learns of the dea th.  In case of death, there should 
be one SAE Zith the outcome of death  reported .  
In the event of a subMectÂ¶s death, it is recommended that the implanted system be e[planted and 
returned to Medtronic for analysis Zhenever possible  per local process .  Local laZs and procedures must 
be folloZed Zhere applicable.  
System Interrogation Data Recommendations:  
x After the subMect has died but prior to e[plant, it is strongly recommended that the system be 
interrogated and a full summary interrogation (Interrogate All) performed Zhen possible, and 
saved in a digital format.  Store one copy of the save -to-media at the site and send a copy to 
Medtronic.   
x MaNe the device interrogation/save -to-media  file before any programming to prevent overZriting 
information in the deviceÂ¶s memory and/or distinguishing betZeen events detected during versus before the e[plant procedure.  
x Recommend obtaining the e[act date and time of death as loZer temperatures after death can cause ERI and other Â³event flagsÂ´ to be stored in the device memory.  
If the system is not interrogated, an e[planation must be entered on the AE form. If any system component is returned to Medtronic, internal return product reporting systems may be used to gather 
additional information about the returned device/component.  
A copy of the death certificate, if available and alloZed by [CONTACT_54443]/local laZ, should be sent to the 
Medtronic ReLINQuish Study  team.  :hen a death occurs in a hospi[INVESTIGATOR_307], a copy of the death summary 
report and all relevant hospi[INVESTIGATOR_241735], if 
available.  If an autopsy is conducted, the autopsy report should also be sent to the Medtronic 
ReLINQuish Study  team if available and alloZed by [CONTACT_54443]/local laZ.  :hen the death occurs at a remote 
site, it is the investigative siteÂ¶s responsibility to attempt retrieval of information about the death.  
Additionally, device disposition information should be updated.  In summary, the folloZing data Zill be 
collected:  
x Date of death  
x Detailed description of death 
x Cause of death  
x Relatedness to system and/or procedure  
x Device interrogation and Save -to-Media  (if available)  
x Device disposition information  
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 54 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.[ADDRESS_293523] 
complaint(s) associated Zith a medical device distributed by [CONTACT_13735], regardless Zhether they are 
related to intended use, misuse or abuse of the product. Reporting must be done immediately and 
via the regular channels for marNet released -products. Medtronic Zill notify the regulatory 
authorities, as applicable for the folloZing incidents immediately upon learning of them:  
x Any malfunction or deterioration in the characteristics and/or performance  of a 
device, as Zell as any inadeTuacy in the labeling or instructions for use Zhich led 
or might have led to the death or serious deterioration in the state of health of a 
patient, user, or other person.  
x Any technical or medical reason resulting in ZithdraZal of a device from the 
marNet by [CONTACT_3455].  
x A serious deterioration in the state of heath includes:  
R Life-threatening illness or inMury, or  
R Permanent impairment of a body structure function or a body function, 
or 
R In-patient or prolonged hospi[INVESTIGATOR_36397]]ation, or 
R Medical or surgical intervention to prevent life -threatening illness or 
inMury or permanent impairment to a body structure or a body function.  
 Data RevieZ &ommitteeV 
The purpose of the study is to characteri]e the relationship betZeen subcutaneous  impedance and 
hemodynamic measurements in patients Zith heart failure.  Additionally, the relationship betZeen changes in subcutaneous  impedance and other physiologic parameters during acute decompensated +F 
events Zill be characteri]ed.   Sinc e this study Zill not proYide effectiYeness and/or safety data an 
independent AdYerse (Yent AdYisory &ommittee A(A& Zill not Ee utili]ed. 4ualified 0edtronic 
personnel Zill reYieZ all adYerse eYents. A Data 0onitoring &ommittee D0& Zill not Ee utili]ed to 
monitor data collected in the study since there are no safety endpoints or planned interim analysis.   
 
 
 StatiVtiFal DeVign anG MetKoGV  
This feasibility study is not poZered to formally test a hypothesis.  +oZever, it is e[pected that a 
sample of up t o 30 subMects Zill be sufficient to determine Zhether this approach Zarrants further 
study.   
 
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 55 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
  (tKiFV  
  Statement(s)  of ComSOiance  
The ReLINQuish study Zill be conducted in compliance Zith international ethical and scientific 
Tuality standards, NnoZn as good clinical practice (GCP). GCP includes revieZ and approval by [CONTACT_241757] a subMect before initiating the study.  
 The ReLINQuish study Zas designed to reflect the GCP principles outlined in ISO [ZIP_CODE]:2011. These include the protection of the rights, safety and Zell-being of human subMects, controls to ensure the scientific conduct and credibility of the clinical investigation and the definition of responsibilities of the sponsor and investigators. In accordance Zith the ISO standard, the sponsor shall avoid 
improper influence on, or inducement of, the subMect, monitor, any investigator(s) or other parties 
participating in, contributing to, the clinical investigation. All investigators shall avoid improper influence on or inducement of the subMect, sponsor, monitor, other investigator(s) or other parties participating in or contributing to the clinical investigation.  
 The study Zill be conducted according to federal, national and local laZs, regulations, standards, 
and reTuirements of the countries/geographies Zhere the study is being conducted. The principles 
of the Declaration of +elsinNi have been implemented through the patient informed consent (PIC) process, IRB approval, study training, clinical trial registration, preclinical testing, risN- benefit 
assessment and publication policy.  
 All investigators are reTuired to complete financial disclosure, as outlined in 21 CFR Part 54 and all 
sites Zill need to comply Zith: 
 
x 21 CFR Part 11 
x 21 CFR Part 50 
x 21 CFR Part 56 
x 21 CFR Part 12(b)  
 
The study Zill be publicly registered on http://clinicaltrials.gov prior to first enrollment in accordance 
Zith the 200 Food and Drug Administration Amendments Act (FDAAA) (PL 110- 5, Section 01(a)) 
and the Declaration of +elsinNi.  
Approval of the CIP is reTuired from the folloZing groups prior to any study procedures at a study center:  
 
x Medtronic  
x An Institutional RevieZ Board at each individual study center  
 
Similarly, approval of subseTuent revisions to the CIP is reTuired at each study center from the above mentioned groups prior to implementation of the revised CIP at that center. 
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 56 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
  StuG\ AGminiVtration  
  Monitoring  
It is the responsibility of Medtronic to ensure proper monitoring of this clinical study.  Trained 
Medtronic personnel or delegates appointed by [CONTACT_241758], the Clinical Trial 
Agreement or :orN Order, and applicable regulatory and local reTuirements. Medtronic, or delegates, must therefore be alloZed access to the subMectsÂ¶ case histories (clinic and hospi[INVESTIGATOR_2553], and other source data/documentation) upon reTuest as per the Informed Consent Form and 
Authori]ation to Use and Disclose Personal +ealth Information/Research Authori]ation/other privacy language (data protection authori]ation) as reTuired by [CONTACT_241759] :orN 
Order.  The principal investigator [INVESTIGATOR_131437].  
Monitoring for the study Zill be done in accordance to the study- specific monitoring plan.  
Monitoring visits may be conducted periodically to assess site study progress, the investigatorÂ¶s adherence to the CIP, regulatory compliance including but not limited to IRB/EC approval and revieZ 
of the study, maintenance of records and reports, and revieZ of source documents against subMect eCRFs. Monitors revieZ site regulatory and study compliance by [CONTACT_54450] -
compliance and communicating those findings along Zith recommendations for preventative/corrective actions to site personnel.  Monitors may ZorN Zith study personnel to 
determine appropriate corrective action recommendations and to identify trends Zithin the study or 
at a particular site. Regulatory documents may be revieZed at each study site. 
  
FreTuency of monitoring visits may be based upon subMect enrollment, duration of the study, study compliance, number of adverse events, number of deviations, findings from previous monitoring 
visits and any suspected inconsistency in data that reTuires investigation.
 
 Data Management
Data Zill be collected using a data management system for clinical studies.  CRF data Zill be stored 
in a secure, passZord -protected database Z hich Zill be bacNed up nightly.  Data Zill be revieZed 
using programmed and manual data checNs.  Data Tueries Zill be made available to centers for resolution.  Study management reports may be generated to monitor data Tuality and study progress.  At the end of the study, the data Zill be fro]en and Zill be retained indefinitely by [CONTACT_13735].  
 All records and other information about subMects participating in this study Zill be treated as 
confidential. Data Zill be transferred and processed by [CONTACT_13757] a  third party designated by 
[CONTACT_54452] a Ney coded form, unless it is impossible to maNe it anonymous, for instance, Zhere the 
patientÂ¶s name [CONTACT_131514], such as fluoroscopy images.   
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 57 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.[ADDRESS_293524]Â¶s record. The CRF may serve has the primary source for the folloZing data points but is not limited to  the list beloZ (refer to the 
study -specific monitoring plan for complete listing).  
 The data reported on the CRFs shall be derived from source documents and be consistent Zith these source documents, and any discrepancies  shall be e[plained in Zriting.  
  Direct Access to Source Data/Documents  
All study investigator(s)/institution(s) Zill permit study- related monitoring, audits, IRB/IEC revieZ, 
and regulatory inspection(s), providing direct access to source data/documents as reTuired in accordance Zith ReLINQuish CIP and the investigator agreement.  
  ConfidentiaOity  
All records and other information about subMects participating in this study Zill be treated as confidential. The identity of a subMect Zill never be disclosed in the event that study data are published.  
SubMect confidentiality Zill be maintained throughout the clinical study in a Zay that ensures the information can alZays be tracNed bacN to the source data. For this purpose, a uniTue subMect identification code Zill be assigned and used to alloZ identification of all data reported for each 
subMect. 
Study data may be made available to third parties, e.g. in the case of an audit performed by 
[CONTACT_12721], provided the data are treated confidentially and that the subMectÂ¶s privacy is guaranteed. Sites Zill maintain subMect privacy according to  local and national regulations and 
institutional reTuirements.  
  CIP Amendments 
Amendments to this Clinical Investigation Plan shall be agreed upon betZeen Medtronic and clinical 
investigator(s) and be recorded Zith a Mustification for the amendments.  
  Record Retention 
The investigator must retain the Investigator Site File, subMect medical files  and CRFs in accordance 
Zith local laZ and regulations for a minimum period of 2 year (or longer if local laZs reTuire) after 
marNet -release in his/her region. The investigator should taNe measures to prevent accidental or 
early destruction of the clinical study related materials.  
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 58 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
   PuEOication and Use of Information 
Publications and presentations referring to this clinical study Zill be coordinated by [CONTACT_241760]. The folloZing publication policy Zill have to be adhered to by [CONTACT_241761] s: 
Medtronic may intend to publish the results of the study in scientific Mournal s and congress es. 
There are no plans to form a publication committee. Publication activities Zill be assessed after the 
study is completed and any collaboration Zith the investigator Zill be determined at that time.  
Authorship on any publication(s) resulting from this clinical study Zill be assigned according to 
substantial contribution s to conception and design, acTuisition of data, or analysis and interpretation 
of data , drafting the article or revising it critically for important intellectual content and final approval 
of the version to be published. This is in accordance Zith the Vancouver principles (The Uniform 
ReTuirements for Manuscripts Submitted to Biomedical -ournals: :riting and Editing for Biomedical Publication, Latest I CM-E Recommendations (Â³Recommendations for the Conduct, Reporting,  
Editing, and Publication of Scholarly :orN in Medical -ournalsÂ´, 2013), as agreed upon by [CONTACT_241762].  
The number of authors Zill be dependent on the regulations of the concerning Mournal .  
Based on the principle that Medtronic oZns the data of this clinical study, a single investigation site 
may access and use the data provided by [CONTACT_241763] . 
Medtronic as the oZner of the data can use the data and/or any results derived from the data or 
publications based on that data for marNeting purposes, further research and development of 
devices or educational use.  
The study sponsor Zill collect data in such Zay that no subMect can be identified, and monitor study records. 
Participating subMects Zill not be identified by [CONTACT_241764].  
  SusSension or EarOy Termination 
14..1.  Planned study closure  
Study Closure is a process initiated by [CONTACT_57661] a study closure letter. Study closure is defined as closure of a clinical study that occurs Zhen Medtronic and/or regulatory reTuirements have been satisfied per the Clinical Investigation Plan and/or by a decision by [CONTACT_131488]), Zhichever occurs first. The study closure process is complete upon distribution of the Final Report or after final payments, Zhichever occurs last. Ongoing IRB oversight is reTuired until 
the overall study closure process is complete. Refer to Section 10. for additional information 
regarding study e[it procedures.  
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 59 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
 14..2. Early termination or suspension
Early Termination of the Study is the closure of a clinical study that occurs prior to meeting defined 
endpoints. This is possible for the Zhole study or a single center. Study Suspension is a temporary 
postponement of study activities related to enrollment and distribution of the product. This is possible for the Zhole study or a single center.  
14..3.  Study -Zide te rmination or suspension 
Possible reasons for considering study suspension or termination of the study include but are not limited to:  
x Adverse events associated Zith the system or product under investigation Zhich might endanger the safety or Zelfare of the  subMect 
x Observed/suspected performance different from the productÂ¶s design intent  
x Decision by [CONTACT_54467] (Zhere the study is operating under regulatory body authority)  
x Technical issues during the manufacturing process  
14..4.  Investigator/center termination or suspension  
Possible reasons for clinical investigator or center termination or suspension include but are not limited to:  
x Failure to obtain initial IRB approval or annual reneZal of the study 
x Persistent non -compliance to the clinical investigation (e.g. failure to adhere to 
inclusion/e[clusion criteria, failure to folloZ subMects per scheduled folloZ -ups)  
x LacN of enrollment  
x Noncompliance to regulations and the terms of the Clinical Trial Agreement (e.g. failure to submit data in a timely manner, failure to folloZ -up on data Tueries and monitoring findings 
in a timely manner, etc.)  
x IRB suspension of the center  
x Fraud or fraudulent misconduct is discovered (as defined by [CONTACT_241765])  
Investigator reTuest (e.g. no longer able to  support the study) . 
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 60 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
 14..5. Procedures for termination or suspension
14..5.1.  Medtronic -initiated and regulatory authority-initiated 
x Medtronic Zill promptly inform the clinical investigators of the termination or suspension and 
the reasons and inform the regulatory authority(ies) Zhere reTuired  
x In the case of study termination or suspension for reasons other than a temporary IRB approval lapse, the investigator Zill promptly inform the IRB  
x In the case of study termination, the investigator must inform the subMects and may inform the personal physician of the subMects to ensure appropriate care and folloZ -up is provided  
x In the case of a study suspension, subMect enrollment must stop until the suspension is lifted by [CONTACT_13735]  
x In the case of a study suspension, enrolled subMects should continue to be folloZed out of consideration of their safety, rights and Zelfare  
 
14..5.2.  Investigator -initiated  
x The investigator Zill inform Medtronic and provide a detailed Zritten e[planation of the termination or suspension  
x The investigator Zill promptly inform the institution (Zhere reTuired per regulatory reTuirements)  
x The investigator Zill promptly inform the IRB  
x The investigator Zill promptly inform the subMects and/or the personal physician of the subMects to ensure appropriate care and folloZ -up is provided  
x In the case of a study suspension, subMects enrolled should continue to be folloZed out of consideration of their safety, rights and Zelfare  
14..5.3.  IRB-initiated  
x The investigator Zill inform Medtronic and provide a detailed Zritten e[planation of the termination or suspension Zithin [ADDRESS_293525] stop until the suspension is lifted  
x SubMects already enrolled should continue to be folloZed in accordance Zith IRB policy or its determination that an overriding safety concern or ethical issue is involved  
x The investigator Zill inform his/her institution (Zhere reTuired per local reTuirements)  
x The investigator Zill promptly inform the subMects, or legally- authori]ed designees or 
guardians and/or the personal physician of the subMects, Zith the rationale for the study termination or suspension  
 
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 61 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
  ReIerenFeV  
x Dra]ner M+, Rame -E, Stevenson L:, Dries DL. Prognostic importance of elevated Mugular 
venous pressure and a third heart sound in patients Zith heart failure. The NeZ England Mournal of medicine. 2001345:54- 51 
x Setoguchi S, Stevenson L:, SchneeZeiss S. Repeated hospi[INVESTIGATOR_36397]]ations predict mortality in the community population Zith heart failure. American heart Mournal. 200154:260- 266 
x Merchant FM, Dec G:, Singh -P. Implantable sensors for heart failure. Circulation. Arrhythmia and electrophysiology. 20103:65- 66 
x Bourge RC, Abraham :T, Adamson PB, Aaron MF, Aranda -M, -r., MagalsNi A, =ile MR, Smith AL, Smart F:, O
Shaughnessy MA, -essup ML, SparNs B, Naftel DL, Stevenson L:. Randomi]ed controlled trial of an implantable continuous hemodynamic monitor in patients Zith advanced heart failure: The compass -hf study. -ournal of the American College of Cardiology. 
20051:103- 10 
x Abraham :T, Adamson PB, Bourge RC, Aaron MF,  Costan]o MR, Stevenson L:, StricNland :, 
Neelagaru S, Raval N, .rueger S, :einer S, Shavelle D, -effries B, <adav -S. :ireless pulmonary artery haemodynamic monitoring in chronic heart failure: A randomised controlled trial. Lancet. 
20113:65- 666 
x <u CM, :ang L, Chau E, Chan R+, .ong SL, Tang MO, Christensen -, Stadler R:, Lau CP. 
Intrathoracic impedance monitoring in patients Zith heart failure: Correlation Zith fluid status and feasibility of early Zarning preceding hospi[INVESTIGATOR_36397]]ation. Circulation. 2005112:41-4  
x =ile MR, Sharma V, -ohnson -:, :arman EN, Baicu CF, Bennett TD. Prediction of all-cause mortality based on the direct measurement of intrathoracic impedance. Circulation. +eart failure. 2016:e002543 
x Tang :+. Case studies in advanced monitoring: Optivol. RevieZs in cardiovascular medicine. 2006 Suppl 1:S62- 66 
x Small RS, :icNemeyer :, [LOCATION_013] R, +oppe B, Andrulli -, Brady PA, Labeau M, .oehler -, SarNar S, +ettricN DA, Tang :+. Changes in intrathoracic impedance are associated Zith subseTuent risN of hospi[INVESTIGATOR_36397]]ations for acute decompensated heart failure: Clinical utility of implanted device monitoring Zithout a patient alert. -ournal of cardiac failure. 20015:45- 41 
x Roy-Chaudhury, P, :illiamson, DE, Tumlin, -A, .her, V., PraNash, ., Charytan DM, TiZari, SC, 
PoNhariyal, S, Podoll, AS. Â³Monitoring in Dialysis (MiD) Study: E[ploring the Timeline and Etiology of Increased Arrhythmias in +emodialysis (+D) Patients.Â´ - Am Soc Nephrol 2015: Late BreaNing Clinical Trial Poster (SA -PO1112).  
x =ielinsNi,  T, et al.  Medtronic Internal Research Report, 2012.  
  
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 62 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
  AppenGiFeV  
Appendi[ A: Patient Informed Consent Form Template  
Appendi[ B: Draft data collection forms (Case Report Forms)  
Appendi[ C: ReLINQuish +andbooN  
Appendi[ D: Site Information  
 
  
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 63 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
 AppenGi[ A: 3atient ,nIormeG &onVent )orm Template  
Template informed consent form Zill Ee proYided under separate coYer.  
 
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 64 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
 AppenGi[ %: DraIt Gata FolleFtion IormV 
Draft data collection forms Zill be provided under separate cover.   
Re/,N4uiVK &liniFal ,nveVtigation 3lan  
  
31 October 2017  Version  2.0 Page 65 of 67 
Medtronic Confidential 
This document is electronically controlled                                               056-F25, v3.0 Clinical Investigation Plan Template   
  
 AppenGi[ &: Re/,N4uiVK StuG\ 3roFeGure +anGEooN  
The ReLINQuish Study Procedre +andbooN Zill be provided under separate cover.  
 